Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00622505 · BASELINE

Baseline characteristics

Zoledronic Acid Treatment (Every 4 or 12 Weeks) to Prevent Skeletal Complications in Advanced Multiple Myeloma Participants · Source last updated 2021-05-26

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      79
    2. group Id
      BG001
      value
      42
    3. group Id
      BG002
      value
      121
    units
    Participants
groups
  1. description
    Participants received 4 mg or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes every 12 weeks for up to 96 weeks based on the participants most recent urine NTx measurement ( \<50 nmol/mmol creatinine).
    id
    BG000
    title
    Zoledronic Acid Every 12 Weeks
  2. description
    Participants received 4 mg or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes every 4 weeks or every 12 weeks for up to 96 weeks based on the participants most recent urine NTx measurement (≥ 50 nmol/mmol creatinine or \<50 nmol/mmol creatinine, respectively).
    id
    BG001
    title
    Zoledronic Acid Every 4 Weeks or 12 Weeks
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          9.91
          value
          62.8
        2. group Id
          BG001
          spread
          12.66
          value
          65.8
        3. group Id
          BG002
          spread
          10.99
          value
          63.8
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          36
        2. group Id
          BG001
          value
          21
        3. group Id
          BG002
          value
          57
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          43
        2. group Id
          BG001
          value
          21
        3. group Id
          BG002
          value
          64
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Intent-to-treat (ITT) analysis set included all participants who were enrolled in this study.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      79
    2. group Id
      BG001
      value
      42
    3. group Id
      BG002
      value
      121
    units
    Participants
groups
  1. description
    Participants received 4 mg or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes every 12 weeks for up to 96 weeks based on the participants most recent urine NTx measurement ( \<50 nmol/mmol creatinine).
    id
    BG000
    title
    Zoledronic Acid Every 12 Weeks
  2. description
    Participants received 4 mg or a reduced dose, i.e., 3.5 mg, or 3.3 mg or 3.0 mg of Zoledronic acid as an IV infusion over a minimum of 15 minutes every 4 weeks or every 12 weeks for up to 96 weeks based on the participants most recent urine NTx measurement (≥ 50 nmol/mmol creatinine or \<50 nmol/mmol creatinine, respectively).
    id
    BG001
    title
    Zoledronic Acid Every 4 Weeks or 12 Weeks
  3. description
    Total of all reporting groups
    id
    BG002
    title
    Total
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          9.91
          value
          62.8
        2. group Id
          BG001
          spread
          12.66
          value
          65.8
        3. group Id
          BG002
          spread
          10.99
          value
          63.8
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          36
        2. group Id
          BG001
          value
          21
        3. group Id
          BG002
          value
          57
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          43
        2. group Id
          BG001
          value
          21
        3. group Id
          BG002
          value
          64
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
population Description
Intent-to-treat (ITT) analysis set included all participants who were enrolled in this study.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice